myelofibrosis


Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

my·e·lo·fi·bro·sis

 (mī′ə-lō-fī-brō′sĭs)
n.
Proliferation of fibroblastic cells in bone marrow, causing anemia and sometimes enlargement of the spleen and liver.

myelofibrosis

(ˌmaɪələʊfaɪˈbrəʊsɪs)
n
(Pathology) a disorder which causes fibrosis of the bone marrow

my•e•lo•fi•bro•sis

(ˌmaɪ ə loʊ faɪˈbroʊ sɪs)
n.
the replacement of bone marrow by fibrous tissue, characteristic of leukemia and certain other diseases.
[1945–50]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.myelofibrosis - fibrosis of the bone marrow
fibrosis - development of excess fibrous connective tissue in an organ
Translations

my·e·lo·fi·bro·sis

n. mielofibrosis, fibrosis de la médula ósea.

myelofibrosis

n mielofibrosis; primary — mielofibrosis primaria
Mentioned in ?
References in periodicals archive ?
The randomized, international, multicenter study compared the efficacy and safety of pacritinib at two dose levels, compared with best available therapy, which included ruxolitinib (a JAK1/JAK2 inhibitor), in patients with myelofibrosis and thrombocytopenia (defined as platelet counts <=100 x 109/L).
In a research note to investors, the analyst said she believes that the primary driver of value for the late-stage clinical biotechnology company is pacritinib, its compound for treatment of patients with myelofibrosis, and that since CTI BioPharma is currently dependent on pre-commercial products and is not yet profitable, she is focusing primarily on potential future revenue to value it.
Pharmaceutical company Imago BioSciences said on Thursday that it has successfully filed its Investigational New Drug (IND) application for IMG-7289 with the US Food and Drug Administration (FDA) for myelofibrosis (MF).
Impact is developing fedratinib for myelofibrosis and polycythemia vera.
Based on the results from two clinical trials, regulatory applications in myelofibrosis are planned beginning in the mid 2018.
Primary myelofibrosis is classified in oncology under myoproliferative neoplasms.
CTI BioPharma has a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis.
Idiopathic Myelofibrosis is a rare myeloproliferative disorder.
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by abnormal proliferation of megakaryocytes, bone marrow fibrosis, and extramedullary hematopoiesis.
WHILE IT usually hits people who are in their 50s and 60s, myelofibrosis strikes deathly fear when it affects young people.
GlobalData's clinical trial report, "Myelofibrosis Global Clinical Trials Review, H1, 2016" provides an overview of Myelofibrosis clinical trials scenario.
Ruxolitinib was initially approved in 2011 for the treatment of intermediate- and high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.